Nieto RJF, Ramírez BJD, Mauricio ÁC, Fernando GL

Idioma: Español
Referencias bibliográficas: 154
Paginas: 41-64
Archivo PDF: 1120.03 Kb.

RESUMEN

El rechazo crónico se ha convertido en la principal causa de disfunción tardía y de pérdida de un aloinjerto. El linfocito B juega un papel amplio en el rechazo crónico de un trasplante y su papel protagónico ha sido enfocado principalmente a la producción de anticuerpos. Sin embargo, es bien conocido que el linfocito B tiene otras funciones importantes que están implicadas en múltiples procesos inmunológicos, pero su rol en el rechazo de los trasplantes no se conoce a profundidad. Estas funciones son: presentación de antígenos y activación de los linfocitos T CD4⁺; regulación por medio de la producción de citoquinas de las células T, células dendríticas y macrófagos; y dirección de la expansión local linfática (linfoangiogénesis) por medio de la producción de factores de crecimiento y quemoquinas. En esta revisión se presenta una visión general de la inmunobiología del trasplante y posteriormente el tema se enfoca en el papel de la célula B en el rechazo crónico de trasplantes, haciendo énfasis en el trasplante renal.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rifle G, Mousson C, Martin L, Guignier F, Hajji K. Donor-specific antibodies in allograft rejection: clinical and experimental data. Transplantation 2005; 79: S14-S18.

2. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 1078-1084.

3. Takemoto S, Port FK, Claas FH, Duquesnoy RJ. HLA matching for kidney transplantation. Hum Immunol 2004; 65: 1489-1505.

4. Vadivel N, Tullius SG, Chandraker A. Chronic allograft nephropathy. Semin Nephrol 2007; 27: 414-429.

5. Gong N, Chen X, Ding Z, Ming C. Chronic allograft nephrophathy: The mechanisms and strategies. Hong Kong J Nephrol 2007; 9: 58-69.

6. Velásquez SY, García LF, Alvarez CM. Las células T reguladoras y su influencia en la sobrevida del trasplante renal. Medicina (Buenos Aires) 2007; 67: 491-501.

7. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282: 111-117.

8. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005; 5: 2611-2618.

9. Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev 2003; 196: 197-218.

10. Solez K, Colvin RB, Racusen LC et al. Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007; 7: 518-526.

11. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.

12. Kamoun M. Mechanisms of chronic allograft dysfunction. Ther Drug Monit 2006; 28: 14-18.

13. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148-157.

14. Vongwiwatana A, Gourishankar S, Campbell PM, Solez K, Halloran PF. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4: 124-129.

15. Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.

16. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673.

17. Zarkhin V, Li L, Sarwal M. “To B or not to B?” Bcells and graft rejection. Transplantation 2008; 85: 1705-1714.

18. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004; 197: 179-191.

19. Rocha PN, Plumb TJ, Crowley SD, Coffman TM. Effector mechanisms in transplant rejection. Immunol Rev 2003; 196: 51-64.

20. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152: 5135-5141.

21. Russell PS, Chase CM, Colvin RB. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997; 64: 1531-1536.

22. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998; 4: 1392-1396.

23. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.

24. Soleimani B, Lechler RI, Hornick PI, George AJ. Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation. Am J Transplant 2006; 6: 1781-1785.

25. Smith JD, Lawson C, Yacoub MH, Rose ML. Activation of NF-kappa B in human endothelial cells induced by monoclonal and allospecific HLA antibodies. Int Immunol 2000; 12: 563-571.

26. Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. Curr Opin Immunol 2003; 15: 487-492.

27. Shi C, Lee WS, He Q et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A 1996; 93: 4051-4056.

28. Wewers MD, Marsh CB. Role of the antibody in the pathogenesis of transplant vascular sclerosis: a hypothesis. Transpl Immunol 1997; 5: 283-288.

29. Noorchashm H, Greeley SA, Naji A. The role of t/b lymphocyte collaboration in the regulation of autoimmune and alloimmune responses. Immunol Res 2003; 27: 443-450.

30. Pelletier RP, Hennessy PK, Adams PW, VanBuskirk AM, Ferguson RM, Orosz CG. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2: 134-141.

31. van Saase JL, van der Woude FJ, Thorogood J et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995; 59: 1280-1285.

32. Sijpkens YW, Doxiadis II, De Fijter JW et al. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 1999; 56: 1920-1927.

33. Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200-1203.

34. Humar A, Payne WD, Sutherland DE, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69: 2357-2360.

35. Joseph JT, Kingsmore DB, Junor BJ et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 2001; 15: 221-227.

36. Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192-1194.

37. Theruvath TP, Saidman SL, Mauiyyedi S et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77-83.

38. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.

39. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement de gradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242-251.

40. Taylor CJ, Chapman JR, Ting A, Morris PJ. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 1989; 48: 953-958.

41. Rodriguez LM, Paris SC, Arbelaez M et al. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007; 68: 652-660.

42. Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant 2001; 16: 897-904.

43. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500.

44. Le Bas-Bernardet S, Hourmant M, Valentin N et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75: 477-482.

45. Vasilescu ER, Ho EK, Colovai AI et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 2006; 67: 597-604.

46. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269-1273.

47. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269-1273.

48. Gloor JM, Sethi S, Stegall MD et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132.

49. Campos EF, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316-2320.

50. Langan LL, Park LP, Hughes TL et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007; 7: 847-856.

51. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.

52. Racusen LC, Colvin RB, Solez K et al. Antibody- mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.

53. Muczynski KA, Cotner T, Anderson SK. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int 2001; 59: 488-497.

54. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008; 8: 492-496.

55. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008; 8: 1367-1373.

56. Le MA, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002; 73: 1373-1381.

57. Susal C, Opelz G. Options for immunologic support of renal transplantation through the HLA and immunology laboratories. Am J Transplant 2007; 7: 1450-1456.

58. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80: 1194-1197.

59. Valujskikh A, Heeger PS. Emerging roles of endothelial cells in transplant rejection. Curr Opin Immunol 2003; 15: 493-498.

60. Reed EF. Signal transduction via MHC class I molecules in endothelial and smooth muscle cells. Crit Rev Immunol 2003; 23: 109-128.

61. Harris PE, Bian H, Reed EF. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 1997; 159: 5697-5704.

62. Bian H, Reed EF. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFNgamma and TNF-alpha. J Immunol 1999; 163: 1010-1018.

63. Jin YP, Singh RP, Du ZY, Rajasekaran AK, Rozengurt E, Reed EF. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol 2002; 168: 5415-5423.

64. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005; 79: S19-S21.

65. Zou Y, Stastny P, Susal C, Dohler B, Opelz G. Antibodies against MICA antigens and kidneytransplant rejection. N Engl J Med 2007; 357: 1293-1300.

66. Rose ML. Activation of autoimmune B cells and chronic rejection. Transplantation 2005; 79: S22-S24.

67. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339: 1566-1570.

68. Fredrich R, Toyoda M, Czer LS et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67: 385-391.

69. Le Bas-Bernardet S, Hourmant M, Coupel S, Bignon JD, Soulillou JP, Charreau B. Non-HLAtype endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003; 3: 167-177.

70. Ball B, Mousson C, Ratignier C, Guignier F, Glotz D, Rifle G. Antibodies to vascular endothelial cells in chronic rejection of renal allografts. Transplant Proc 2000; 32: 353-354.

71. Jaramillo A, Naziruddin B, Zhang L et al. Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for bronchiolitis obliterans syndrome. Transplantation 2001; 71: 966-976.

72. Jurcevic S, Ainsworth ME, Pomerance A et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886-892.

73. Nair S MAHA. Immunisation with vimentin causes rejection of syngeneic cardiac grafts. J Heart Lung Transplant 2004; 23: S132.

74. Bravo J, Quiroz Y, Pons H et al. Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition. Kidney Int Suppl 2003; (86):S46-S51.

75. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003; 5: 59-63.

76. Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.

77. Bates RL, Frampton G, Rose ML, Murphy JJ. High diversity of non-human leukocyte antigens in transplant-associated coronary artery disease. Transplantation 2003; 75: 1347-1350.

78. Joosten SA, van Dixhoorn MG, Borrias MC et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 1301-1310.

79. Joosten SA, Sijpkens YW, van H, V et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5: 383-393.

80. Akalin E, Watschinger B. Antibody-mediated rejection. Semin Nephrol 2007; 27: 393-407.

81. Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.

82. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 2232-2239.

83. Bohmig GA, Exner M, Habicht A et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099.

84. Bohmig GA, Regele H, Exner M et al. C4dpositive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482-2489.

85. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334-341.

86. Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-241.

87. Regele H, Exner M, Watschinger B et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 2058-2066.

88. Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787.

89. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395-400.

90. Zou Y, Heinemann FM, Grosse-Wilde H et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the posttransplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67: 230-237.

91. Akalin E, Murphy B, Seghal B, Schroppel B, Boccardo G, Bromberg J. Low prevalence of C4d positivity in chronic allograft nephropathy and transplant glomerulopathy biopsies. J Am Soc Nephrol 2006; 17.

92. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008; 69: 591-604.

93. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: whose problem is it? Front Biosci 2008; 13: 1396-1412.

94. Christiaans MH, Overhof-de RR, Nieman F, van Hooff JP, van den Berg-Loonen EM. Donor- specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 1998; 65: 427-433.

95. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008; 180: 2357-2366.

96. Haas M, Montgomery RA, Segev DL et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-585.

97. Gjertson DW. A multi-factor analysis of kidney regraft outcomes. Clin Transpl 2002; 335-349.

98. Truong DQ, Darwish AA, Gras J et al. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement. Transpl Immunol 2007; 17: 283-287.

99. Golocheikine AS, Saini D, Ramachandran S, Trulock EP, Patterson A, Mohanakumar T. Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation. Transpl Immunol 2008; 18: 260-263.

100. Sayegh MH. Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney Int 1999; 56: 1967-1979.

101. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001; 12: 2500-2506.

102. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-214.

103. Noorchashm H, Reed AJ, Rostami SY et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006; 177: 7715-7722.

104. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H, Jr. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001; 167: 5522-5526.

105. Yamada A, Laufer TM, Gerth AJ et al. Further analysis of the T-cell subsets and pathways of murine cardiac allograft rejection. Am J Transplant 2003; 3: 23-27.

106. Guillonneau C, Aubry V, Renaudin K et al. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. Transplantation 2005; 80: 546-554.

107. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002; 2: 945-956.

108. Mak TW, Shahinian A, Yoshinaga SK et al. Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. Nat Immunol 2003; 4: 765-772.

109. Nurieva RI, Mai XM, Forbush K, Bevan MJ, Dong C. B7h is required for T cell activation, differentiation, and effector function. Proc Natl Acad Sci U S A 2003; 100: 14163-14168.

110. Liang L, Sha WC. The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol 2002; 14: 384-390.

111. Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS. J Autoimmun 2003; 21: 255-260.

112. Ozkaynak E, Gao W, Shemmeri N et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591-596.

113. Mitchison NA. T-cell-B-cell cooperation. Nat Rev Immunol 2004; 4: 308-312.

114. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005; 5: 230-242.

115. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000; 290: 84-89.

116. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277-285.

117. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell deficient mice results in T helper cell type 1 deviation. J Exp Med 2000; 192: 475-482.

118. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-496.

119. Kaser A, Dunzendorfer S, Offner FA et al. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol 2000; 165: 2474-2480.

120. Krzysiek R, Lefevre EA, Zou W et al. Antigen eceptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. J Immunol 1999; 162: 4455-4463.

121. Evans JG, Chavez-Rueda KA, Eddaoudi A et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178: 7868-7878.

122. Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 2007; 179: 7225-7232.

123. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219-230.

124. Wolf SD, Dittel BN, Hardardottir F, Janeway CA, Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996; 184: 2271-2278.

125. Watanabe R, Fujimoto M, Ishiura N et al. CD19 expression in B cells is important for suppression of contact hypersensitivity. Am J Pathol 2007; 171: 560-570.

126. Brummel R, Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005; 174: 2429-2434.

127. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950.

128. Mauri C, Ehrenstein MR. The ‘short’ history of regulatory B cells. Trends Immunol 2008; 29: 34-40.

129. Clatworthy MR, Smith KG. B cells in glomerulonephritis: focus on lupus nephritis. Semin Immunopathol 2007; 29: 337-353.

130. Kerjaschki D, Regele HM, Moosberger I et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603-612.

131. Cassese G, Lindenau S, de BB et al. Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001; 31: 2726-2732.

132. Desvaux D, Le GS, Pastural M et al. Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome. Nephrol Dial Transplant 2004; 19: 933-939.

133. Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002; 22: 317-349.

134. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol 2004; 172: 5143-5148.

135. Alexandre GP, Squifflet JP, De BM et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19: 4538-4542.

136. Shishido S, Asanuma H, Tajima E et al. ABOincompatible living-donor kidney transplantation in children. Transplantation 2001; 72: 1037-1042.

137. Tang AH, Platt JL. Accommodation of grafts: implications for health and disease. Hum Immunol 2007; 68: 645-651.

138. Yu PB, Holzknecht ZE, Bruno D, Parker W, Platt JL. Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. J Immunol 1996; 157: 5163-5168.

139. Mohiuddin MM, Ogawa H, Yin DP, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation 2003; 75: 258-262.

140. Soares MP, Brouard S, Smith RN, Bach FH. Heme oxygenase-1, a protective gene that prevents the rejection of transplanted organs. Immunol Rev 2001; 184: 275-285.

141. Tabata T, de PM, Keshavjee S, Liu M, Downey GP, Waddell TK. Accommodation after lung xenografting from hamster to rat. Transplantation 2003; 75: 607-612.

142. Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260-269.

143. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004; 34: 2303-2312.

144. Park WD, Grande JP, Ninova D et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3: 952-960.

145. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 2004; 78: 1471-1478.

146. Kirk AD, Baldwin WM, Cascalho MI, Chong AS, Sykes M, West LJ. American society of transplantation symposium on B cells in transplantation: harnessing humoral immunity from rodent models to clinical practice. Am J Transplant 2007; 7: 1464-1470.

147. King KE, Warren DS, Samaniego-Picota M, Campbell-Lee S, Montgomery RA, Baldwin WM, III. Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol 2004; 16: 545-549.

148. Ishida H, Tanabe K, Ishizuka T et al. The mechanism responsible for accommodation after living-related kidney transplantations across the blood barrier. Transpl Int 2005; 18: 716-720.

149. Wang N, Lee JM, Tobiasch E et al. Induction of xenograft accommodation by modulation of elicited antibody responses1 2. Transplantation 2002; 74: 334-345.

150. Green DR. Overview: apoptotic signaling pathways in the immune system. Immunol Rev 2003; 193: 5-9.

151. Defrance T. Mature B cells: apoptosis checkpoints. Transplantation 2005; 79: S4-S7.

152. Creagh EM, Conroy H, Martin SJ. Caspaseactivation pathways in apoptosis and immunity. Immunol Rev 2003; 193: 10-21.

153. Hennino A, Berard M, Krammer PH, Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med 2001; 193: 447-458.

154. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001; 1: 50-58.